Listed companies of Vandetanib

Vandetanib (Vandetanib) was approved by the U.S. Food and Drug Administration (FDA) in April 2011 for the treatment of advanced thyroid cancer. Vandetanib was initially marketed without a trade name; it has been marketed under the trade name Caprelsa since August 2011. Genzyme acquired the product from AstraZeneca in 2015.

Vandertanib is a prescription drug used to treat medullary thyroid cancer that cannot be removed with surgery or has spread to other parts of the body. It takes a long time to clear vandetanib from the body, and patients may be at risk for vandetanib-related side effects after stopping treatment. It is not known whether vandetanib is safe and effective in children. Vandetanib is a kinase inhibitor. Kinases are enzymes that signal other molecules in cells, including cancer cells, to become active. Vandetanib interferes with cell communication and may prevent tumor growth. It is also important to note that normal cells may be affected by vandetanib treatment, which may cause side effects. In the ZETA study, vandetanib showed a 65% relative reduction in the risk of progression compared with placebo. This means that taking vandetanib may prolong progression-free survival (PFS).

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.